34.97

3.34% 1.185

Tyra Biosciences Inc (TYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Tyra Biosciences Inc stock is traded at $34.97, with a volume of 1.06M. It is up +3.34% in the last 24 hours and up +0.90% over the past month. Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Previous Close:

$33.78

Open:

$34.24

24h Volume:

1.06M

Relative Volume:

1.02

Market Cap:

$2.08B

Revenue:

Net Income/Loss:

$-119.95M

P/E Ratio:

-17.38

EPS:

-2.0123

Net Cash Flow:

$-95.28M

1W Performance:

-4.85%

1M Performance:

+0.90%

6M Performance:

+122.65%

1Y Performance:

+238.95%

1-Day Range:

$33.99

$35.45

1-Week Range:

$33.30

$38.63

52-Week Range:

$8.75

$40.65

Tyra Biosciences Inc Stock (TYRA) Company Profile

Name

Tyra Biosciences Inc

Sector

Healthcare (1115)

Industry

Biotechnology (620)

Phone

(619) 728-4760

Address

2656 STATE STREET, CARLSBAD

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

TYRA's Discussions on Twitter

Compare TYRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TYRA Tyra Biosciences Inc	35.05	2.09B	0	-119.95M	-95.28M	-2.0123
VRTX Vertex Pharmaceuticals Inc	428.05	109.41B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	705.55	76.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.85	48.20B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	305.80	40.31B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	296.74	33.13B	5.36B	287.73M	924.18M	2.5229

Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Guggenheim	Buy
Apr-06-26	Initiated	Canaccord Genuity	Buy
Feb-24-26	Initiated	Cantor Fitzgerald	Overweight
Feb-10-26	Initiated	William Blair	Outperform
Jan-28-26	Initiated	Barclays	Overweight
Sep-03-25	Initiated	Raymond James	Strong Buy
May-21-25	Resumed	Piper Sandler	Overweight
Jan-07-25	Initiated	UBS	Buy
Oct-18-24	Upgrade	BofA Securities	Neutral → Buy
Aug-15-24	Initiated	Piper Sandler	Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Jun-30-23	Initiated	Wedbush	Outperform
Feb-03-23	Initiated	Oppenheimer	Outperform
Jun-23-22	Initiated	H.C. Wainwright	Buy
Mar-08-22	Upgrade	Jefferies	Hold → Buy
Nov-08-21	Downgrade	Jefferies	Buy → Hold
Oct-11-21	Initiated	BofA Securities	Buy
Oct-11-21	Initiated	Cowen	Outperform
Oct-11-21	Initiated	Jefferies	Buy

View All

Tyra Biosciences Inc Stock (TYRA) Latest News

Apr 29, 2026

TYRA SEC FilingsTyra Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 29, 2026

Tyra Biosciences faces earnings test ahead of key trial data By Investing.com - Investing.com Canada

Apr 29, 2026

Tyra Biosciences faces earnings test ahead of key trial data - Investing.com UK

Apr 29, 2026

Apr 27, 2026

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 27, 2026

Apr 26, 2026

Guggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendation - MSN

Apr 26, 2026

Does Tyra Biosciences (TYRA) Board Refresh and Dabogratinib Spotlight Reframe Its Pipeline Credibility? - Sahm

Apr 26, 2026

Apr 25, 2026

Guggenheim Securities Issues Buy Rating for Tyra Biosciences - HarianBasis.co

Apr 25, 2026

Apr 24, 2026

Canaan reports 750,000 shares in Tyra Biosciences (NASDAQ: TYRA) - Stock Titan

Apr 24, 2026

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib - Yahoo Finance

Apr 24, 2026

Apr 23, 2026

Understanding the Setup: (TYRA) and Scalable Risk - Stock Traders Daily

Apr 23, 2026

Top 10 AI-Powered Biotech Stocks to Buy Right Now - Insider Monkey

Apr 23, 2026

Apr 22, 2026

Tyra Biosciences (TYRA) Stock: Entry Strategy Overview | Q4 2025: EPS Misses EstimatesCommunity Buy Signals - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 20, 2026

44,400 Tyra Biosciences (TYRA) stock options granted to director Dable - Stock Titan

Apr 20, 2026

Tyra Biosciences (TYRA) director Dable Habib J files Form 3 showing no share ownership - Stock Titan

Apr 20, 2026

William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛

Apr 20, 2026

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors - marketscreener.com

Apr 20, 2026

Apr 18, 2026

Tyra Biosciences adds Habib Dable to board of directors By Investing.com - Investing.com India

Apr 18, 2026

Apr 17, 2026

Yuliya Rueb Net Worth (2026) - GuruFocus

Apr 17, 2026